Increasing studies have demonstrated that RIP1K is a crucial mediator of apoptotic and necrotic cell death as well as inflammatory pathways, resulting in that RIPK1 kinase has emerged as a promising therapeutic target for the treatment of a wide range of human diseases or conditions, including acute neuronal injury such as ischemic brain injury and traumatic brain injury and neurodegenerative, autoimmune, and inflammatory diseases. This evidence concerns the gene RIPK1 and brain injury.